ABT
Abbott Laboratories·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABT
Abbott Laboratories
A global healthcare leader that develops generic pharmaceuticals, diagnostic systems, nutritional supplements, vascular, and ophthalmic products
Healthcare Equipment and Supplies
--
03/01/1937
New York Stock Exchange
114,000
12-31
Common stock
100 Abbott Park Road, Abbott Park, Illinois 60064-6400
Discover, develop, manufacture and sell a wide range of healthcare products
Abbott is an Illinois corporation incorporated in 1900. Abbott's primary business is the discovery, development, manufacture and sale of a wide range of healthcare products. The company has four reportable divisions: existing pharmaceuticals, diagnostic products, nutritional products and medical devices.
Company Financials
EPS
ABT has released its 2025 Q3 earnings. EPS was reported at 1.3, versus the expected 1.3, meeting expectations. The chart below visualizes how ABT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ABT has released its 2025 Q3 earnings report, with revenue of 11.37B, reflecting a YoY change of 6.90%, and net profit of 1.64B, showing a YoY change of -0.12%. The Sankey diagram below clearly presents ABT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
